Xia Tang

Discovery of Hexahydrofuro[3,2-b]furans as New Kinase-Selective and Orally Bioavailable JAK3 Inhibitors for the Treatment of Leukemia Harboring a JAK3 Activating Mutant.

Zheng-chao Tu, Zhen Wang, Zhengqiu Li, 2022, Journal of medicinal chemistry.

Design, synthesis and biological evaluation of 3-(imidazo[1,2-a]pyrazin-3-ylethynyl)-2-methylbenzamides as potent and selective pan-tropomyosin receptor kinase (TRK) inhibitors.

Yong Xu, Lei Zhang, Xiaoyun Lu, 2019, European journal of medicinal chemistry.

Identification of U937JAK3-M511I Acute Myeloid Leukemia Cells as a Sensitive Model to JAK3 Inhibitor

Zheng-chao Tu, Ke Ding, Zhang Zhang, 2022, Frontiers in Oncology.

JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo

Xiaoyun Lu, Zheng-chao Tu, Ke Ding, 2022, Molecules.

Discovery of D6808, a Highly Selective and Potent Macrocyclic c-Met Inhibitor for Gastric Cancer Harboring MET Gene Alteration Treatment.

Zheng-chao Tu, Zhang Zhang, L. Qu, 2022, Journal of medicinal chemistry.

GZD824 overcomes FGFR1‐V561F/M mutant resistance in vitro and in vivo

Zheng-chao Tu, K. Ding, Zhang Zhang, 2021, Cancer medicine.

GZD824 as a FLT3, FGFR1 and PDGFRα Inhibitor Against Leukemia In Vitro and In Vivo

Zheng-chao Tu, Ke Ding, Zhang Zhang, 2020, Translational oncology.